Cart
sales@molnova.com
JSH-23
CAS No. 749886-87-1
JSH-23( NF-κB Activation Inhibitor II )
Catalog No. M15858 CAS No. 749886-87-1
JSH-23 is an inhibitor of NF-κB transcriptional activity with IC50 of 7.1 μM.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 2MG | 47 | In Stock |
|
| 5MG | 77 | In Stock |
|
| 10MG | 110 | In Stock |
|
| 25MG | 177 | In Stock |
|
| 50MG | 267 | In Stock |
|
| 100MG | 408 | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameJSH-23
-
NoteResearch use only, not for human use.
-
Brief DescriptionJSH-23 is an inhibitor of NF-κB transcriptional activity with IC50 of 7.1 μM.
-
DescriptionJSH-23 is an inhibitor of NF-κB transcriptional activity with IC50 of 7.1 μM.(In Vitro):JSH-2 (1-300 μM; 24 hours) at <100 μM does not show significant cytotoxic effects on the RAW 264.7 cells.Nuclear amount of NF-κB p65 is markedly increased upon exposure to LPS for 1 h. Treatment of JSH-23 (30 μM; 1 hours) to LPS- stimulated RAW 264.7 cells decreases nuclear content of NF-κB p65 in a dose-dependent manner.(In Vivo):JSH-23 (1 mg/kg, 3 mg/kg; orally administered; daily; for 2 weeks) significantly reverses the nerve conduction and nerve blood flow deficits seen in diabetic rats.
-
In VitroJSH-2 (1-300 μM; 24 hours) at <100 μM does not show significant cytotoxic effects on the RAW 264.7 cells.Nuclear amount of NF-κB p65 is markedly increased upon exposure to LPS for 1 h. Treatment of JSH-23 (30 μM; 1 hours) to LPS- stimulated RAW 264.7 cells decreases nuclear content of NF-κB p65 in a dose-dependent manner.Cell Cytotoxicity Assay Cell Line:Macrophages RAW 264.7 Concentration:1, 3, 10, 30, 100, 300 μM Incubation Time:24 hours Result:Did not show significant cytotoxic effects at <100 μM.Western Blot Analysis Cell Line:Macrophages RAW 264.7 with LPS-stimulated Concentration:30 μM Incubation Time:1 hour Result:Decreased nuclear content of NF-κB p65 in a dose-dependent manner, corresponding to 49±4% inhibition at 3 μM, 75±7% at 10 μM and 95±8% at 30 μM.
-
In VivoJSH-23 (1 mg/kg, 3 mg/kg; orally administered; daily; for 2 weeks) significantly reverses the nerve conduction and nerve blood flow deficits seen in diabetic rats. Animal Model:Male Sprague Dawley diabetic rats (250-270 g)Dosage:1 mg/kg, 3 mg/kg Administration:Orally administered; daily; for 2 weeks Result:Produced significant improvement in motor nerve conduction velocity (MNCV).
-
SynonymsNF-κB Activation Inhibitor II
-
PathwayApoptosis
-
TargetNF-κB
-
RecptorNF-κB
-
Research AreaCancer
-
Indication——
Chemical Information
-
CAS Number749886-87-1
-
Formula Weight240.34
-
Molecular FormulaC16H20N2
-
Purity>98% (HPLC)
-
SolubilityEthanol: 20 mg/mL (83.21 mM); DMSO: 48 mg/mL (199.71 mM)
-
SMILESNC1=CC(C)=CC=C1NCCCC2=CC=CC=C2
-
Chemical Name4-methyl-N1-(3-phenylpropyl)benzene-1,2-diamine
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.Kasparkova J, et al. FEBS J. 2014, doi: 10.1111/febs.1271
molnova catalog
related products
-
14-Deoxy-1112-didehy...
14-Deoxy-1112-didehydroandrographolide has hypotensive anti-inflammatory anti-asthma and anti-cancer actions. It can inhibit NF-κB activation.
-
Scandoside
Scandoside, a cyclic enolide that can be isolated from Haemophilus difficile, exhibits anti-inflammatory activity, inhibits the expression levels of inducible nitric oxide synthase (iNOS), cyclooxygenase-2 (COX-2), TNF-α, and IL-6 messenger RNA (mRNA), and inhibits the nuclear transcription factor, kappa-B alpaha (IκB-α), p38, extracellular signal-regulated kinase (ERK) and c-Jun N-terminal kinase (JNK) inhibitor phosphorylation.
-
NF-κB-IN-1
NF-κB-IN-1 is a potent NF-κB signaling pathway inhibitor. It is a 4-arylidene crucumin analogue. NF-κB-IN-1 directly inhibits IKK to block NF-κB activation.
